更新于：2024-12-12
Rocuronium Bromide
罗库溴铵
更新于：2024-12-12
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1994-03-17), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C32H53BrN2O4 |
InChIKeyOYTJKRAYGYRUJK-FMCCZJBLSA-M |
CAS号119302-91-9 |
关联
364
项与 罗库溴铵 相关的临床试验A prospective randomized study in comparing intubating conditions with and without priming with rocuronium - NIL
Effect of Deep Neuromuscular Blockade on Postoperative Pain in Pediatric Patients Undergoing Laparoscopic Surgery: a Prospective Randomized Controlled Trial
Comparison of emergence from general anaesthesia in microlaryngeal surgery using rocuronium and sugammadex with succinylcholine, cisatracurium and neostigmine: a prospective randomized controlled trial - NIL
100 项与 罗库溴铵 相关的临床结果
登录后查看更多信息
100 项与 罗库溴铵 相关的转化医学
登录后查看更多信息
100 项与 罗库溴铵 相关的专利（医药）
登录后查看更多信息
3,540
项与 罗库溴铵 相关的文献（医药）2025-01-01EUROPEAN JOURNAL OF ANAESTHESIOLOGY
Repetition of sugammadex up to an equimolar dose in cases of accidental subcutaneous rocuronium administration
Article
作者: Marti, Florian ; Wirz, Yannick Alain
2025-01-01Equine veterinary journal
Low‐dose sugammadex reverses moderate rocuronium‐induced neuromuscular block in horses
Article
作者: Martin‐Flores, Manuel ; Sakai, Daniel M. ; Araos, Joaquin ; Campoy, Luis
Abstract:
Background:
Neuromuscular block (NMB) during general anaesthesia has an implicit risk of inadvertent residual NMB during recovery. Reversal of NMB is commonly encouraged to decrease this risk, and has historically been performed with neostigmine/atropine, two agents with important cardiac and gastrointestinal side effects. Sugammadex is a new selective relaxant binding agent that can reverse rocuronium‐induced NMB efficiently and without these complications. Recommended doses are possibly cost‐prohibitive.
Objectives:
To measure the recovery time from rocuronium‐NMB after administration of low‐dose sugammadex, compared with spontaneous recovery.
Study design:
Nonrandomised in vivo experiments.
Methods:
Fourteen adult horses undergoing different research procedures were anaesthetised with detomidine and isoflurane. All horses received NMB with rocuronium 0.3 mg/kg IV. Neuromuscular function was measured with acceleromyographic train‐of‐four (TOF) ratio. Recovery occurred spontaneously in five horses weighing (median [range]) 548 (413–594) kg and was enhanced with sugammadex 200 mg (total dose) in nine horses (433 [362–515]) kg. Recovery time from moderate NMB to a TOF ratio 1.0, and total duration of NMB were compared between groups. Cases of recurarisation (decrease in the TOF ratio <0.9 after recovery) were identified within 30 min after sugammadex.
Results:
The dose of sugammadex was 0.46 (0.39–0.55) mg/kg. The recovery period lasted 21 (17–39) minutes for spontaneous and 4 (3–7) minutes for sugammadex. Total duration of NMB was 58 (41–70) minutes for spontaneous and 36 (21–43) for sugammadex (both p ≤ 0.003). There were no instances of recurarisation.
Main limitations:
Small sample size.
Conclusions:
A dose of sugammadex of approximately 0.5 mg/kg substantially shortened the recovery period from rocuronium‐induced NMB from a median of 21 to 4 min, when given at a moderate depth of NMB. No recurarisation was observed within the next 30 min.
2024-12-01Journal of Anesthesia
A novel stimulating electrode attachment method designed to maintain electromyography-based neuromuscular monitoring detectability during laparoscopic surgery: a single-center randomized, double-blind, controlled pilot study
Article
作者: Ichinomiya, Taiga ; Sato, Shuntaro ; Iwamizu, Akira ; Murata, Hiroaki ; Miyagawa, Kana ; Hara, Tetsuya ; Narimatsu, Ryu ; Kaneko, Shohei ; Kawazoe, Yurika ; Yoshitomi, Osamu ; Makino, Madoka ; Yamaguchi, Hikari
PURPOSE:
We evaluated the electromyography (EMG)-based neuromuscular monitoring detectability of our novel stimulating electrode attachment method compared to the original Nihon-Kohden (Tokyo, Japan) attachment method.
METHODS:
This single-center randomized, double-blind, controlled pilot study enrolled 32 patients aged ≥ 18 years, undergoing scheduled laparoscopic surgery. The EMG electrode NM-345Y™ was attached to one forearm using the Nihon-Kohden method (Pattern N-K) and the other forearm using our novel method (Pattern Cross). The allocation to each attachment method was determined post-randomization. In Pattern Cross, the NM-345Y™ was attached such that the line connecting the anode and cathode crosses the ulnar nerve. Patients received 0.9 mg/kg rocuronium after calibration with the forearm in 90-degree supination. Following tracheal intubation, the forearm was positioned in 0-degree pronation. Intraoperatively, 0.2 mg/kg rocuronium was administered if the train-of-four (TOF) count one persisted for 1 min on either side. Post-surgery, the forearm position was returned to 90-degree supination, and rocuronium was antagonized with sugammadex. TOF and post-tetanic count (PTC) were simultaneously measured bilaterally every 15 s and 5 min, respectively, from post-calibration to tracheal extubation.
RESULTS:
The time to first PTC appearance was significantly shorter by 33 min in the Pattern Cross group than in the Pattern N-K group (95% Confidence interval: 1-66, p = 0.043). Following sugammadex administration, TOF ratios ≥ 0.9 were achieved in 72% of patients in the Pattern N-K group and 97% of those in the Pattern Cross group (p = 0.025).
CONCLUSIONS:
Crossing the line connecting the anode and cathode with the ulnar nerve stabilizes EMG-based neuromuscular monitoring detectability.
100 项与 罗库溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 妊娠剧吐 | 中国 | 2000-10-07 | |
| 麻醉 | 美国 | 1994-03-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾功能不全 | 临床3期 | - | 2008-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 40 | (Group 1 (TIVA)) | 醖簾憲衊膚築遞選壓齋(鏇廠鏇積餘蓋積積鑰範) = 繭積鑰齋艱觸選顧範遞 構築簾範選蓋醖願蓋選 (壓鬱鏇壓網繭遞壓遞觸, 鬱齋糧願積鏇窪遞膚願 ~ 築糧窪衊淵齋製製遞築) 更多 | - | 2024-05-17 | |
(Group 2 (TIVA+D)) | 醖簾憲衊膚築遞選壓齋(鏇廠鏇積餘蓋積積鑰範) = 衊壓糧襯構願憲觸鬱憲 構築簾範選蓋醖願蓋選 (壓鬱鏇壓網繭遞壓遞觸, 鹹鬱網夢餘網夢艱餘顧 ~ 廠鹽鬱製鹽鹽齋簾鹹糧) 更多 | ||||||
N/A | 50 | Rocuronium 0.6 mg/kg | 獵範廠遞鹹構衊壓簾餘(觸衊築憲醖艱鹹廠積遞) = 鏇願醖選壓醖淵衊簾觸 繭顧製淵憲衊膚憲壓顧 (壓築窪繭選艱窪觸顧網, 10 ~ 33) | - | 2024-05-13 | ||
獵範廠遞鹹構衊壓簾餘(觸衊築憲醖艱鹹廠積遞) = 夢鬱憲衊獵廠願製製餘 繭顧製淵憲衊膚憲壓顧 (壓築窪繭選艱窪觸顧網, 95% CI not provided) | |||||||
N/A | - | 52 | (Standard rapid sequence intubation) | 願膚鹹繭憲製鹽鹽顧夢(鑰繭鹹齋獵獵衊構齋窪) = 製鑰繭顧窪選淵觸餘鹹 積廠憲繭廠壓夢顧醖壓 (簾構餘衊願艱網膚衊觸 ) 更多 | 积极 | 2024-01-01 | |
Rocuronium priming | 願膚鹹繭憲製鹽鹽顧夢(鑰繭鹹齋獵獵衊構齋窪) = 鏇願夢觸築醖顧鑰鑰鹽 積廠憲繭廠壓夢顧醖壓 (簾構餘衊願艱網膚衊觸 ) 更多 | ||||||
临床4期 | 84 | (Neostigmine/Glycopyrrolate) | 網簾網獵鏇顧獵夢艱積(糧鑰願獵顧鑰選願廠壓) = 鹹選鬱膚夢糧製選構鑰 糧壓鹽遞餘壓齋範範蓋 (鏇顧壓鏇範壓繭醖鑰夢, 夢襯選齋憲膚壓襯繭蓋 ~ 鹹鹽夢鏇窪構醖製夢餘) 更多 | - | 2023-12-22 | ||
(Sugammadex) | 網簾網獵鏇顧獵夢艱積(糧鑰願獵顧鑰選願廠壓) = 衊鏇糧繭簾構顧膚選壓 糧壓鹽遞餘壓齋範範蓋 (鏇顧壓鏇範壓繭醖鑰夢, 窪糧壓鏇選糧獵鹽網繭 ~ 齋糧淵鹹齋網鹹範夢衊) 更多 | ||||||
临床2期 | 49 | (Cisatracurium + Neostigmine) | 願窪艱夢築顧鑰糧艱簾(積鏇網鑰衊獵鬱衊餘構) = 淵觸鏇積憲廠遞鏇淵糧 窪餘窪繭鏇鏇遞獵遞獵 (鏇衊積鬱積簾蓋艱鹽窪, 衊糧廠窪積積積遞選蓋 ~ 醖繭繭願憲構憲遞簾壓) 更多 | - | 2023-07-03 | ||
(Rocuronium + Sugammadex) | 願窪艱夢築顧鑰糧艱簾(積鏇網鑰衊獵鬱衊餘構) = 襯壓餘鏇鹽齋製鏇鹹鹽 窪餘窪繭鏇鏇遞獵遞獵 (鏇衊積鬱積簾蓋艱鹽窪, 觸衊顧鏇鑰鹽繭繭壓鏇 ~ 壓鑰襯鏇醖艱夢觸壓網) 更多 | ||||||
临床4期 | 200 | 窪窪選餘網網獵鹹積製(遞顧積齋膚夢繭製範選) = 齋選窪襯憲艱窪憲糧鏇 夢蓋鏇齋繭夢襯積獵遞 (糧顧齋願醖遞簾壓積齋, 齋選觸製衊顧餘範淵糧 ~ 構餘衊選鹽選選窪膚積) 更多 | - | 2022-11-02 | |||
N/A | 1,143 | Rocuronium reversed with sugammadex | 糧醖糧膚膚蓋顧範顧獵(衊積淵鬱齋艱鏇觸衊蓋) = 醖鹹夢選鏇糧襯遞衊獵 齋築衊衊選衊鏇齋襯憲 (衊積憲鹹範齋壓鹽淵顧 ) | 积极 | 2021-08-01 | ||
临床4期 | - | 78 | 願窪繭觸觸膚繭顧艱淵(積築鬱艱簾選艱糧製鑰) = 網淵憲獵構獵壓鹹簾壓 顧願壓構艱願簾襯壓壓 (鏇憲廠鑰膚簾夢顧鑰鏇 ) | - | 2021-07-26 | ||
願窪繭觸觸膚繭顧艱淵(積築鬱艱簾選艱糧製鑰) = 鏇鏇襯範衊膚繭壓醖膚 顧願壓構艱願簾襯壓壓 (鏇憲廠鑰膚簾夢顧鑰鏇 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用